Kenvue Inc. (NYSE:KVUE – Get Free Report) announced a quarterly dividend on Thursday, October 17th, RTT News reports. Investors of record on Wednesday, November 13th will be given a dividend of 0.205 per share on Wednesday, November 27th. This represents a $0.82 annualized dividend and a yield of 3.77%.
Kenvue has a payout ratio of 67.2% indicating that its dividend is sufficiently covered by earnings. Research analysts expect Kenvue to earn $1.23 per share next year, which means the company should continue to be able to cover its $0.82 annual dividend with an expected future payout ratio of 66.7%.
Kenvue Stock Down 0.1 %
Shares of KVUE opened at $21.73 on Thursday. The company has a current ratio of 0.99, a quick ratio of 0.68 and a debt-to-equity ratio of 0.69. Kenvue has a 12 month low of $17.67 and a 12 month high of $23.55. The stock’s 50 day moving average is $22.24 and its two-hundred day moving average is $20.19. The firm has a market cap of $41.61 billion, a P/E ratio of 27.86, a PEG ratio of 2.76 and a beta of 1.40.
Analysts Set New Price Targets
KVUE has been the topic of several research reports. JPMorgan Chase & Co. raised their target price on Kenvue from $24.00 to $25.00 and gave the company an “overweight” rating in a research report on Friday, October 11th. Royal Bank of Canada downgraded Kenvue from an “outperform” rating to a “sector perform” rating and set a $24.00 target price on the stock. in a research report on Tuesday, September 24th. Jefferies Financial Group assumed coverage on Kenvue in a research report on Tuesday, September 24th. They set a “buy” rating and a $27.00 price objective on the stock. Piper Sandler lifted their price objective on Kenvue from $20.00 to $21.00 and gave the stock a “neutral” rating in a research report on Monday, September 23rd. Finally, UBS Group lifted their price objective on Kenvue from $20.00 to $22.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 7th. One analyst has rated the stock with a sell rating, seven have given a hold rating and three have issued a buy rating to the stock. According to MarketBeat.com, Kenvue has a consensus rating of “Hold” and an average price target of $22.20.
View Our Latest Report on KVUE
About Kenvue
Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.
Read More
- Five stocks we like better than Kenvue
- When to Sell a Stock for Profit or Loss
- Why Buffett Loves Occidental Stock And What It Means for Chevron
- How to Use the MarketBeat Excel Dividend Calculator
- UnitedHealth Group Pulls Back Into a Healthy Buying Opportunity
- How to Start Investing in Real Estate
- Why Alphabet Could Rally 30% Before Christmas
Receive News & Ratings for Kenvue Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kenvue and related companies with MarketBeat.com's FREE daily email newsletter.